I do tend to agree that the drug will not "roar out of the gate," but once doctors fully understand what I explained above, I do expect the device to do very well, perhaps reaching peak sales of $200 million if marketed correctly. Otrexup, for the reasons I mention is not a "me-too" device, but rather a "hey, I'm easier to use than a standard needle for both patients and care givers, plus I'm biodegradable, so I'm easier on the environment."
Antares is also developing Vibex QST, a quick shot testosterone self-injector. Vibex-QST is designed to offer a once-a-week subcutaneous injection solution for those suffering from low testosterone (Low-T). Antares is seeking to prove in clinical trials that Vibex-QST will offer better efficacy and cost effectiveness in comparison to Low-T gel solutions, which are applied on a daily basis. If Antares is successful with Vibex-QST, this product can be a monetary "blockbuster" for the company within five years.
Additionally, as brought to my attention by long-time Antares investor, "lokodude" (Lokodaug on Yahoo boards) the company holds patents to, and is developing the following products:
- Ovaleap pen (Follitropin alfa)—Pat # 8376993 - "Multiple Dosage injector"
- Valebo (Teriparatide)—Pat # 8376993 - "Multiple Dosage injector"
- Lonquex (Lipegfilgrastim)—US 20130018354 - "Cammed ram Assembly" injector
- Alazmia-Balugrastim—US 20130018354 - "Cammed ram Assembly" injector
- Granix (tbo-filgrastim)—US 20130018354 -"Cammed ram Assembly" injector
In addition to these patents, Antares has a patent for scopolamine, which is a tropane alkaloid drug with muscarinic antagonist effects. In other words, the drug is designed to potentially treat depression.
While it's too early to say what Antares will do specifically with its scopolamine patent, it will be interesting to watch how the company proceeds in time. We believe that Antares is a safer long-term investment, which could also be acquired in the short term due to its connection with Pfizer (PFE).